Patent · US Expired

Modified recombinant vaccinia virus and expression vectors thereof

US5762938A · kind A · utility

66Cited by
7References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 21, 1996
Grant dateJun 9, 1998
Priority date
Expiry dateAug 21, 2016

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/826
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant vaccinia virus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence. In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor. In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.